Dashboard · Pharmaceuticals stocks · GLENMARK
60
JayScore

Glenmark Pharmaceuticals Limited

GLENMARK Pharmaceuticals
Positive Setup Grade A 56% confidence
Score computed at ₹2,640.00 · 16 Nov 2026
Research signals 0 positive · 8 cautionary of 8
NSE
JayScore
60
vs
Sector signal
6
60
Glenmark Pharmaceuticals Limited GLENMARK Positive Setup
Get notified when this stock's JayScore changes
Free account — score alerts, daily research picks, morning plan and portfolio tracker.
Sign Up Free Sign In
About Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited is a Pharmaceuticals company listed on the National Stock Exchange (NSE) with a market capitalisation of ₹74,507 crore. The company reports ROE of 14%, a net profit margin of 9.1%. Revenue grew -29.8% year-over-year. Promoter holding stands at 49%, with FII participation at 27.5%.

Pharmaceuticals sector signal: 6/100 — below-average — fewer than 40% of sector peers are trading above their EMA 20.
JayScore 60/100 indicates a moderate research signal — some positive factors present but mixed signals overall. JayScore is a quantitative index — not investment advice. Learn how it's calculated →
JaySense Research View · quantitative signals only · not investment advice
Positive Setup

Price is rising consistently (EMA alignment — short and medium-term averages both pointing up). Buying pressure is building (RSI/MACD momentum confirmed). Trading near its strongest price of the year (within 5% of 52-week high). A trend-following indicator is on the bullish side (SuperTrend signal: buy). The uptrend is visible even on the weekly chart (longer-term trend confirmed). Short-term oscillator is overheated — entering now means chasing (StochRSI above 80, late entry risk). Both short and medium-term trend lines are pointing upward — the trend has momentum (rising EMA20 + EMA50). Price is right at the ceiling of this year's range — a close above would be a significant breakout (at 52W high zone). Foreign institutions have been net buyers for 3 consecutive days — sustained institutional demand (✅ FII buying streak).

Positive Signals
Price is trending above key moving averages
Watch Points
Volume is below average — move lacks conviction
Fundamental score is weak relative to benchmark
Valuation appears stretched on current metrics
Growth momentum has slowed materially
Elevated risk signals detected in this stock
Institutional activity is low or declining
⚠ Low volume — today's volume is below the confirmation threshold. Swing entry not ideal; monitor for volume pickup.
Research Score Insight

Glenmark Pharmaceuticals Limited scores 60/100 (Positive Research Signal). The strongest signals are Trend (17/100) and Momentum (13/100). The weakest dimension is Growth (0/100), which warrants monitoring. This reflects JaySense quantitative research scoring only — not investment advice. Consult a SEBI Registered Investment Adviser before making any investment decision.

Trend 17 Momentum 13 Volume 0 Fundamental 2 Valuation 0 Growth 0 Institutional 2 Sector 6 Risk 2
Research Intelligence Free Account Required
0 positive · 9 risk signals identified 3 / 9 signals converging
Downtrend active — price has broken below key moving averages
Institutional indicators suggest active accumulation in this price zone
Volatility ratio and momentum signal caution at current levels
Institutional indicators suggest active accumulation in this price zone
Volatility ratio and momentum signal caution at current levels

8 more research signals — available free with a JaySense account

Get Free Access Sign in
Sector & Institutional Activity Free Account Required
Sector Health
6.4000/100
Sector Rank
#3 of 12
FII Activity
Net Buying
FII net buyers ₹840 Cr over last 10 sessions — institutional accumulation in progress
DII activity supportive — domestic funds adding to position

Sector peer rank, FII/DII trend & institutional activity — free with a JaySense account

Get Free Access Sign in
Score Analysis
Trend
17
Weak
Price vs moving averages · trend structure
Momentum
13
Weak
MACD · RSI · rate-of-change
Volume
0
Weak
Volume strength · accumulation vs distribution
Fundamental
2
Weak
Margins · returns · debt ratios
Valuation
0
Weak
PE · PB · multiples vs sector
Growth
0
Weak
Revenue & profit growth YoY
Sector
6
Weak
Sector relative strength vs market
Risk
2
Weak
Volatility · beta · drawdown risk
Institutional
2
Weak
FII / DII participation & block deals
Signal convergence: 3 / 9 dimensions aligned · Low convergence
Score Trend (Last 30 Scores)
Fundamentals
Market Cap
₹74,507 Cr
P/E Ratio
51.35
P/B Ratio
6.65
EPS (TTM)
51.41
ROE
14%
ROCE
—
Net Profit Margin
9.1%
Debt / Equity
12.55
Revenue Growth YoY
-29.8%
Profit Growth YoY
-56.8%
Promoter Holding
49%
FII Holding
27.5%
Dividend Yield
0.2%
Company Profile
Glenmark Pharmaceuticals Limited is a Pharmaceuticals company listed on the National Stock Exchange (NSE) with a market capitalisation of ₹74,507 crore. The company reports ROE of 14%, a net profit margin of 9.1%. Revenue grew -29.8% year-over-year. Promoter holding stands at 49%, with FII participation at 27.5%.
Corporate Actions
Corporate Actions Source: NSE
Recent History
₹2.50 / share
31 Aug 2026
Dividend
Related Research — Same Sector
Stock Score Signal
SUNPHARMA
Sun Pharmaceutical Industries Limited
84 High Conviction
AUROPHARMA
Aurobindo Pharma Limited
75 High Conviction
APOLLOHOSP
Apollo Hospitals Enterprise Limited
73 High Conviction
DIVISLAB
Divi's Laboratories Limited
72 High Conviction
CIPLA
Cipla Limited
69 Positive Setup
How JaySense scores stocks Full stock screener
Disclaimer: JaySense scores are research outputs based on technical and fundamental signals. They are not buy/sell recommendations and do not constitute investment advice. Past score performance does not guarantee future returns. Please do your own research or consult a SEBI-registered investment advisor before making any investment decision. JaySense is not SEBI-registered. Use this platform for educational and research purposes only.